Navigation Links
CuraGen Presents Update on Clinical Development Program for,Belinostat

- Clinical activity reported against CTCL, PTCL and Ovarian Cancers -

BRANFORD, Conn., June 12, 2007 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, presented today an update on the clinical development program for belinostat, a histone deacetylase (HDAC) inhibitor, and reported updated results suggesting clinical activity of belinostat against cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and ovarian cancers.

A conference call is being hosted at 8:30 a.m. Eastern time on June 12, 2007, to review these results including data presented at the 2007 Pan Pacific Lymphoma Conference being held this week in Maui, HI, and data presented at the 2007 American Society of Clinical Oncology (ASCO) meeting.

"We are very impressed by the emerging data on intravenous belinostat in the treatment of solid and hematologic cancers, both as a single agent and in combination with other chemotherapeutic agents. These results, along with additional data actively being generated, are helping us to refine the potential indications for belinostat and to enable us to develop an appropriate plan for our Phase III program," commented Frank Armstrong, M.D., President and Chief Executive Officer of CuraGen.

CLN-6: Phase II trial evaluating intravenous belinostat for T-cell Lymphomas

The interim results reported on 14 patients with CTCL and 12 patients with PTCL. In the CTCL arm in patients who had received an average of six prior lines of therapy, four of 14 patients achieved an objective response for an objective response rate of 29% including one complete response (CR) and three partial responses (PR). Time to response ranged from 8-57 days. As demonstrated by a decrease in SWAT score, 77% of evaluable patients showed an improvement in skin burden of CTCL. Five out of six patients with significant pruritus at baseline had a cl
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
2. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:6/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... its common stock consisting of 1,475,506 shares to be ... by certain of its stockholders. In addition, Nevro expects ... up to an additional 590,202 shares of common stock ...
(Date:6/1/2015)... , June 1, 2015 NEOVIA ONCOLOGY ... engaged in the development and commercialization of novel, ... it has met with the U.S. Food and ... filing of an Investigational New Drug (IND) application ... a result of the meeting, Neovia has clarified ...
(Date:6/1/2015)... Novel t reatments   entering the squamous ... GBI Research . The ... primarily by the introduction of numerous premium therapies, particularly in ... combine with generic chemotherapies. Analysis from business intelligence ... to 2020 - forecasts the value of the NSCLC ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Neovia Oncology Announces First IND Meeting 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3
... Pharmasset, Inc.,(Nasdaq: VRUS ), a clinical stage pharmaceutical ... viral,infections, reported financial results for the fiscal year ended September ... cash and cash,equivalents and short term investments. , ... Clevudine , ...
... PHILADELPHIA, December 11, Rosetta Genomics, Ltd. (NASDQ: ROSG), ... the,commercial availability of its first diagnostic test, miRview(TM) ... Genomics,CLIA-certified lab in Philadelphia. , ... may contact 1-888-522-7971, or visit the,company,s website ...
Cached Medicine Technology:Pharmasset Reports Fiscal Year End 2008 Financial Results 2Pharmasset Reports Fiscal Year End 2008 Financial Results 3Pharmasset Reports Fiscal Year End 2008 Financial Results 4Pharmasset Reports Fiscal Year End 2008 Financial Results 5Pharmasset Reports Fiscal Year End 2008 Financial Results 6Pharmasset Reports Fiscal Year End 2008 Financial Results 7Pharmasset Reports Fiscal Year End 2008 Financial Results 8Pharmasset Reports Fiscal Year End 2008 Financial Results 9Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 2Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 3Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 5
(Date:6/1/2015)... June 01, 2015 KC and Monica ... $88,000 of the best superfood products in ... floods in Texas. , "Monica and I are ... News in distributing Living Fuel Super Meals - SuperBerry®, ... millennial floods in Texas," KC Craichy said. "We have ...
(Date:6/1/2015)... Atlanta, GA (PRWEB) June 01, 2015 ... leading publisher of clinical journals in the areas of ... pleased to announce that it has expanded upon its ... newest journal, Hospital Medicine Practice, in a mobile ... smartphones and tablets. , “We are very excited ...
(Date:6/1/2015)... The session, entitled “Building the Blueprint for Tomorrow’s Vehicle ... Automotive Americas, senior representatives from Ford and Delphi, ... by Andy Gryc of CX3 Marketing. The discussion will ... software in connected vehicles and autonomous cars, and will ... ecosystem can fit into new vehicle software. , ...
(Date:6/1/2015)... Strategic Radiology (SR) announced today that Rome Radiology Group ... SR coalition of progressive, independent radiology groups geographically dispersed ... have access to collective resources in all aspects of ... of subspecialized radiology services. With the addition of RRG, ... based radiology group practices. , “We are all ...
(Date:6/1/2015)... PA (PRWEB) June 01, 2015 It ... and sanitary in order to protect both care providers ... that there needs to be a way to put ... Line is a line of home-healthcare products that promotes ... care providers and patients safe from germs and disease. ...
Breaking Medicine News(10 mins):Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 2Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 2Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 4
... came into being in the seventies, evolved into an essential component ... increase with mounting pressure on pharma and biotech companies to lower ... projected to exceed $26.2 billion by the year 2012. , ... ...
... that allows more efficient use of larger cleanrooms. , ... ... designer, fabricator and installer of cleanrooms and cleanroom equipment ... into the AireCell line of extrusions. The new extrusion allows ...
... SuperFood with Super Antioxidant provides ... environmental stress, ORLANDO, Fla., Oct. 21 ... (Chennai, India) are jointly introducing a,new organic ... complex,of organic spirulina and astaxanthin in a ...
... 21, 2008) Gastroesophageal reflux disease (GERD) is ... in GI and primary care clinics, however physicians ... trials of medications and their own observations and ... Gastroenterological Association (AGA) Institute has published evidence-based guidelines ...
... of $25 Tickets Available for Purchase at the Pine Avenue ... Entrance to the Long Beach Convention Center, LOS ANGELES, ... The Village event tonight from 5:00 p.m. to 9:00 p.m.,at the ... Night at The Village will,transform the Long Beach Convention Center,s exhibit ...
... Promotes Positive Options, Educates about Dangers of Alcohol, ... 24 school districts have been named by the ... 2008 Alcohol Awareness Poster,Contest., The awards recognize ... message that underage drinking is dangerous. The,PLCB,s annual ...
Cached Medicine News:Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 2Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 3Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 4Health News:Gerbig Engineering Introduces 7 " Deep Extrusions for Cleanroom Construction 2Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 2Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 3Health News:AGA releases evidence-based GERD guidelines 2Health News:AGA releases evidence-based GERD guidelines 3Health News:Maria Shriver to Debut 'Night at The Village' Event with Rachael Ray, Billie Jean King, Dr. Mehmet Oz and Rocco DiSpirito 2Health News:Maria Shriver to Debut 'Night at The Village' Event with Rachael Ray, Billie Jean King, Dr. Mehmet Oz and Rocco DiSpirito 3Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 2Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 3Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 4
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.2 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled double bevel. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 2.85 mm slit. Blade tip dimension: 14.1 mm x 2.85 mm x 3.3 mm....
Full Handle Laseredge Slit Blade Knife, 2.8 mm angled double bevel. Blade tip dimension: N/A x 2.8 mm x N/A....
Medicine Products: